Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BHC
Strong BuyFull HouseBausch Health Companies Inc. · Healthcare · Canada · $2.4B · Avg Vol: $31M/d
COMPANY DESCRIPTION
Bausch Health Companies Inc. develops, manufactures, and markets a diverse portfolio of pharmaceutical products, with a strong presence in eye health (Bausch + Lomb), gastroenterology, and dermatology. The company maintains a significant global footprint and established brands within its therapeutic areas, particularly benefiting from its legacy Bausch + Lomb business. BHC is in a transformational phase, actively de-leveraging and streamlining its operations, including the spin-off of its eye care business.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.1B | 8.8B | 9.6B | 10.3B | 8.1% | 10.9B | 10.9B | 10.9B | 3.0% |
| EPS | -0.62 | -1.62 | -0.13 | 0.42 | — | -2.94 | 0.50 | 0.47 | 5.8% |
| Shares | 361.9M | 365.2M | 367.8M | 370.5M | +2.4% | 374.0M | — | — | — |
| Debt | 20.8B | 22.4B | 21.6B | 20.9B | 0.1% | 20.8B | — | — | — |
| Equity | -692.0M | -1.0B | -1.3B | -554.0M | — | — | — | — | — |
| Op CF | -728.0M | 1.0B | 1.6B | 1.4B | 16.5% | 1.8B | — | — | — |
| Inv CF | -303.0M | -2.1B | -454.0M | -595.0M | — | — | — | — | — |
| Fin CF | -474.0M | 1.5B | -868.0M | -742.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BHC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BHC | Bausch Health Companies Inc.(you) | $2.4B | 89 | Strong Buy |
| CRON.TO | Cronos Group Inc. | $1.2B | 73 | Buy |
| GUD.TO | Knight Therapeutics Inc. | $682M | 77 | Buy |
| CPH.TO | Cipher Pharmaceuticals Inc. | $265M | 93 | Strong Buy |
| XLY.TO | Auxly Cannabis Group Inc. | $232M | 98 | Strong Buy |
| APTX.TO | Apotex Health Corp. | $5.4B | 46 | Hold |
| RX.V | BioSyent Inc. | $130M | 92 | Strong Buy |
| MDP.TO | Medexus Pharmaceuticals Inc. | $118M | 90 | Strong Buy |
| LOVE.TO | Cannara Biotech Inc. | $141M | 95 | Strong Buy |
| TSND.TO | TerrAscend Corp. | $243M | 61 | Hold |
Peer medians: ROE -37.9% · P/E 17.3x · Gross margin 44.2%